Tezspire

Active Ingredient(s): Tezepelumab-ekko
FDA Approved: * December 17, 2021
Pharm Company: * ASTRAZENECA AB
Category: Asthma

Tezepelumab, sold under the brand name Tezspire, is a human monoclonal antibody used for the treatment of asthma.[4][5] It blocks thymic stromal lymphopoietin (TSLP),[2] an epithelial cytokine that has been suggested to be critical in the initiation and persistence of airway inflammation.[6] It was approved for medical use in the United States in December 2021.[2][3] Contents 1 Medical uses 2 Re... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Tezspire 210 mg/1.9ml Subcutaneous Injection, Solution
NDC: 55513-100
Labeler:
Amgen, Inc
Tezspire 210 mg/1.9ml Subcutaneous Injection, Solution
NDC: 55513-112
Labeler:
Amgen, Inc
Tezspire 210 mg/1.9ml Subcutaneous Injection, Solution
NDC: 55513-123
Labeler:
Amgen, Inc